



Hunstman Cancer Institute becomes the first Mediso Preclinical Imaging Center of Excellence in North America

Salt Lake City, UT, USA and Boston, MA, USA – 10 September, 2015 –The [Center for Quantitative Cancer Imaging](#) at [Huntsman Cancer Institute](#) (HCI), part of the University of Utah Health Care system in Salt Lake City, UT, has become the first site in North America to be designated as a Center of Excellence for Preclinical Imaging by [Mediso Ltd.](#) and its affiliate company [Mediso USA](#).

Two multi-modality nanoScan *in vivo* preclinical imaging systems have been installed at HCI: a [nanoScan PET/MRI](#), combining positron emission tomography (PET) and magnetic resonance imaging (MRI) techniques in one integrated system, and a [nanoScan SPECT/CT](#), combining single photon emission tomography (SPECT) and x-ray computed tomography (CT) in one combined system. Both systems seamlessly integrate four imaging modalities without any compromise in image quality, performance and ease of use.

According to Jeffrey Yap, Ph.D., Associate Director of the Center for Quantitative Cancer Imaging at Huntsman Cancer Institute and Research Associate Professor in the Department of Radiology at the University of Utah, “This combination of scanners provides a wide range of options for anatomical, functional, and molecular imaging, including the ability to perform imaging of animals in a single session with four different modalities that are spatially co-registered.”

“HCI has an outstanding ranking in the field of cancer research. This is further emphasized by the fact that HCI has been recently awarded Comprehensive Cancer Center status by the National Cancer Institute (NCI). We are proud to receive the possibility to support the focus of HCI scientists to create safer and more effective treatments for the patients”, say Illes Muller, Managing Partner of Mediso USA. “HCI researchers have decades of combined clinical and preclinical multi-modality imaging experience. HCI provides a unique combination with the possibility to perform quantitative preclinical imaging covering four modalities – PET, SPECT, MRI and CT. The researchers are able to select any combination of the modalities to interrogate a wide range of biological questions by using the common building blocks developed by Mediso, including the Nucline acquisition framework and the MultiCell animal handling and monitoring system.”